Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1537-2995.2007.01498.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Apatinib and trastuzumab-based chemotherapy for heavily treated primary trastuzumab-resistant metastatic breast cancer.
J Cancer Res Ther
December 2024
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People's Republic of China.
Article Synopsis
- The study examines the effects of a combination therapy (apatinib and trastuzumab-based chemotherapy) on patients with primary trastuzumab resistance (PTR) in HER2-positive breast cancer.
- A total of 20 PTR patients were treated, showing a clinical benefit rate of 55%, though no complete responses were observed, and median progression-free survival was 5.7 months.
- While the treatment had manageable side effects, further research is recommended to better identify which PTR patients could potentially benefit from this therapy.
Comparative retrospective analysis of cord blood transplantation with ATG-containing conditioning regimens and haploidentical stem cell transplantation: similar survival outcomes with reduced incidence of GVHD.
Ann Med
December 2025
Department of Hematology, Peking University First Hospital, Beijing, China.
Background: Cord blood (CB) is widely used in treating haematologic disorders due to its broad availability, tolerance to significant histocompatibility antigen disparities, and low incidence of chronic graft-versus-host disease (cGVHD). The cord blood transplantation (CBT) with anti-thymocyte globulin (ATG)-containing conditioning regimens shows promise in this regard.
Methods: We conducted a retrospective review of data from patients who underwent CBT at our centre from August 2003 to December 2022.
Echinococcosis: An Uncommon Cause of Thoracic Pain.
Cureus
November 2024
Internal Medicine, Centro Hospitalar Universitário de Lisboa Central, Lisbon, PRT.
Echinococcosis is caused by larvae, the metacestode stage of the tapeworm , and poses a public health issue in many developing countries. It generally affects a single organ, most commonly the liver or lungs, and rarely involves multiple organs. We present the case of a 24-year-old Indian man living in Portugal, who was admitted to the Emergency Department with left-sided thoracic pain radiating to the back.
View Article and Find Full Text PDFCat scratch disease in children with nocturnal fever: A case report.
World J Clin Cases
December 2024
Department of Pediatric Intensive Care Unit, Rainbow Hospital of Xianyang (Children's Hospital of Xianyang), Xianyang 721000, Shaanxi Province, China.
Background: Cat scratch disease (CSD) is the most common human infection caused by (). The main manifestation is self-limited lymphadenopathy that primarily affects adolescents, and typically resolves without treatment within 2-4 months. However, individuals with compromised immune systems or immunodeficiency require specific antibacterial therapy following diagnosis.
View Article and Find Full Text PDFEfficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1.
Int J Clin Oncol
December 2024
Department of Hematology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Hokkaido, Japan.
Background: In a global phase I/II study (GO29781; NCT02500407), single-agent mosunetuzumab had a manageable safety profile and induced durable complete responses in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma, including in patients with R/R follicular lymphoma (FL). In this analysis, the efficacy and safety of mosunetuzumab monotherapy were evaluated in an expansion cohort, FLMOON-1, in Japanese patients with R/R FL who had received ≥ 2 prior lines of therapy in a phase I study (JO40295, jRCT2080223801).
Methods: Mosunetuzumab was administered intravenously at the recommended phase II dose (with cycle 1 step-up dosing) for eight cycles or up to 17 cycles, or until disease progression or unacceptable toxicity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!